Acne Medication Market By Type (Topical Retinoid & Combination Retinoid, Oral Retinoid (Isotretinoin), Topical Antibiotic & Combination Antibiotics, Oral Antibiotics, Salicylic Acid, Benzoyl Peroxide, and Others), By Application (Prescription Medicine and Over-the-counter (OTC) Medicine), Industry Trends, Estimation & Forecast, 2023-2030

Market Definition

Acne is a chronic skin condition that causes pimples and spots on the face, neck, chest, shoulders, back, and upper arms. Acne medications reduce oil production, fighting bacterial infection, speeding up skin cell turnover, and reducing inflammation. Acne medications include topical retinoid & combination retinoid, oral retinoid (Isotretinoin), topical antibiotic & combination antibiotics, oral antibiotics, salicylic acid, benzoyl peroxide, and others.

The Acne Medication market was valued at 3054.6 million US$ in 2022 and is projected to reach 4444.7 million US$ by 2030, at a CAGR of 4.8% during the forecast period.

Acne Medication Market Revenue By, 2022-2030

Market Dynamics

Increasing regulatory approval of acne medication is driving the global acne medication market. For instance, The U.S. Food and Drug Administration (FDA) has approved ARAZLO (tazarotene) Lotion from Bausch Health Companies Inc. ARAZLO is a topical treatment of acne vulgaris for patients nine years and older. ARAZLO is the first tazarotene acne treatment in a lotion form. Additionally, the U.S. Food and Drug Administration (FDA) has approved AMZEEQ (minocycline) topical foam by Foamix Pharmaceuticals Ltd. AMZEEQ was formerly known as FMX101, indicated for the treatment of moderate to severe acne vulgaris in pediatric and adult patients nine years of age and older. AMZEEQ is the first topical minocycline to be approved by the FDA for any conditions. Further, the rising prevalence of acne is a key factor in boosting the market. According to the World Health Organization (WHO), globally, acne affected more than 633 million people, making it the most common disease worldwide. More than 90% of the world population is affected by acne at some point in their life. However, the side effect associated with acne medication might hamper the market growth. Side effects of acne treatments are based on the method of medication.

Topical acne drugs, most common side effects are skin dryness, irritation, skin itches, burns, and peels heavily. Moreover, increasing clinical studies on acne medication would provide lucrative opportunities for the market in the coming years.

Market Segmentation

The global acne medication market is mainly classified based on type and application. Type is further segmented into Topical Retinoid & Combination Retinoid, Oral Retinoid (Isotretinoin), Topical Antibiotic & Combination Antibiotics, Oral Antibiotics, Salicylic Acid, Benzoyl Peroxide, and Others. By application, the market is divided into Prescription Medicine and Over-the-counter (OTC) Medicine.

Topical Retinoid & Combination Retinoid had shown significant growth in 2019, owing to the increasing clinical studies on a topical retinoid, awareness program for acne treatment, the partnership between companies to develop and supply topical retinoid, and the commercialization of regulatory approved topical retinoid. For instance, Galderma has received the U.S. Food and Drug Administration (FDA) approval for AKLIEF cream for the topical treatment of acne. AKLIEF Cream is the first topical treatment studied and proven to treat both facial and truncal acne.

Regional Analysis

Based on geography, the global acne medication market is divided into North America, Europe, Asia-Pacific, South America, and Middle East & Africa. North America is further divided in the U.S., Canada, and Mexico, whereas Europe consists of the UK, Germany, France, Italy, and Rest of Europe. Asia-Pacific is segmented into India, China, Japan, South Korea, and Rest of Asia-Pacific. The South America region includes Brazil, Argentina, and the Rest of South America, while the Middle East & Africa is categorized into GCC Countries, Egypt, South Africa, and Rest of Middle East & Africa.

North America was dominating the global acne medication market in 2019, due to the rising prevalence of acne in North American countries. According to the American Academy of Dermatology Association, acne affects more than 60 million Americans annually. Around 85% of people between the ages of 12 and 24 have the least minor acne. Acne vulgaris affects 80% of Americans and 20% have severe acne at some point during their lives. Moreover, rising awareness of acne medication in the U.S and increasing clinical studies on acne medications are some of the factors boosting the market growth. For instance, Vyome Therapeutics has completed the Phase 2 trial of VB-1953. VB-1953 is a first-in-class topical bactericidal and TLR-MD2 inhibitor developed for the treatment of moderate to severe inflammatory facial acne vulgaris.

Competitive landscape

Key players operating in the acne medication industry include Galderma S.A., Allergan Plc, Mylan N.V., Johnson & Johnson, Mayne Pharma Group Limited, Sun Pharmaceutical Industries Limited, Valeant Pharmaceuticals International, Inc., Teva Pharmaceutical Industries Ltd., Foamix Pharmaceuticals, and Daiichi Sankyo Company, Ltd.

The commercialization of regulatory approved acne medication, increasing clinical studies on acne medication, a rising awareness program for acne, and the partnership between companies to develop, regulatory approval and market acne medication are some of the strategies adopted by the major companies. For instance, Certara partnered with Galderma to receive FDA approval of AKLIEF topical acne cream. AKLIEF (trifarotene) Cream, is used for the topical treatment of acne. Trifarotene is the first retinoid molecule to receive FDA approval to treat acne.

Acne Medication Market Key Segments:

By Type
• Topical Retinoid & Combination Retinoid
• Oral Retinoid (Isotretinoin)
• Topical Antibiotic & Combination Antibiotics
• Oral Antibiotics
• Salicylic Acid
• Benzoyl Peroxide
• Others

By Application
• Prescription Medicine
• Over-the-counter (OTC) Medicine

Key Global Acne Medication Industry Players
• Galderma S.A.
• Allergan Plc
• Mylan N.V.
• Johnson & Johnson
• Mayne Pharma Group Limited
• Sun Pharmaceutical Industries Limited
• Valeant Pharmaceuticals International, Inc.
• Teva Pharmaceutical Industries Ltd.
• Foamix Pharmaceuticals
• Daiichi Sankyo Company, Ltd.

1. Market Introduction
1.1. Executive Summary
1.2. Market Definition
1.3. Market Scope

2. Research Methodology
2.1. Primary Research
2.2. Research Methodology
2.3. Assumptions & Exclusions
2.4. Secondary data sources

3. Acne Medication Market Overview
3.1. Report Segmentation & Scope
3.2. Key Market Trend
3.3. Drivers
3.3.1. Increasing Regulatory Approval of Acne Medication
3.3.2. Rising Prevalence of Acne
3.4. Restraints
3.4.1. Side Effect Associated with Acne Medication
3.5. Opportunity
3.5.1. Increasing Clinical Studies on Acne Medication
3.6. Porter’s Five Forces Analysis
3.6.1. Porter’s Five Forces Analysis
3.7. Market Share Analysis

4. Type Overview
4.1. Introduction
4.1.1. Market Size & Forecast
4.2. Topical Retinoid & Combination Retinoid
4.2.1. Market Size & Forecast
4.3. Oral Retinoid (Isotretinoin)
4.3.1. Market Size & Forecast
4.4. Topical Antibiotic & Combination Antibiotics
4.4.1. Market Size & Forecast
4.5. Oral Antibiotics
4.5.1. Market Size & Forecast
4.6. Salicylic Acid
4.6.1. Market Size & Forecast
4.7. Benzoyl Peroxide
4.7.1. Market Size & Forecast
4.8. Others
4.8.1. Market Size & Forecast

5. Application Overview
5.1. Introduction
5.1.1. Market Size & Forecast
5.2. Prescription Medicine
5.2.1. Market Size & Forecast
5.3. Over-the-counter (OTC) Medicine
5.3.1. Market Size & Forecast

6. Acne Medication Market Regional Overview
6.1. Introduction
6.1.1. Market Size & Forecast
6.2. North America Acne Medication Market
6.2.1. North America Market Size & Forecast, By Country
6.2.2. North America Market Size & Forecast, By Type
6.2.3. North America Market Size & Forecast, By Application
6.2.4. U.S.
6.2.4.1. Market Size and Forecast
6.2.5. Canada
6.2.5.1. Market Size and Forecast
6.2.6. Mexico
6.2.6.1. Market Size and Forecast
6.3. Europe Acne Medication Market
6.3.1. Europe Market Size & Forecast, By Country
6.3.2. Europe Market Size & Forecast, By Type
6.3.3. Europe Market Size & Forecast, By Application
6.3.4. Germany
6.3.4.1. Market Size and Forecast
6.3.5. France
6.3.5.1. Market Size and Forecast
6.3.6. UK
6.3.6.1. Market Size and Forecast
6.3.7. Italy
6.3.7.1. Market Size and Forecast
6.3.8. Spain
6.3.8.1. Market Size and Forecast
6.3.9. Rest of Europe
6.3.9.1. Market Size and Forecast
6.4. Asia-Pacific Acne Medication Market
6.4.1. Asia-Pacific Market Size & Forecast, By Country
6.4.2. Asia-Pacific Market Size & Forecast, By Type
6.4.3. Asia-Pacific Market Size & Forecast, By Application
6.4.4. Japan
6.4.4.1. Market Size and Forecast
6.4.5. China
6.4.5.1. Market Size and Forecast
6.4.6. Australia
6.4.6.1. Market Size and Forecast
6.4.7. India
6.4.7.1. Market Size and Forecast
6.4.8. South Korea
6.4.8.1. Market Size and Forecast
6.4.9. Rest of Asia-Pacific
6.4.9.1. Market Size and Forecast
6.5. South America Acne Medication Market
6.5.1. South America Market Size & Forecast, By Country
6.5.2. South America Market Size & Forecast, By Type
6.5.3. South America Market Size & Forecast, By Application
6.5.4. Brazil
6.5.4.1. Market Size and Forecast
6.5.5. Argentina
6.5.5.1. Market Size and Forecast
6.5.6. Rest of South America
6.5.6.1. Market Size and Forecast
6.6. Middle East & Africa Acne Medication Market
6.6.1. Middle East & Africa Market Size & Forecast, By Country
6.6.2. Middle East & Africa Market Size & Forecast, By Type
6.6.3. Middle East & Africa Market Size & Forecast, By Application
6.6.4. GCC Countries
6.6.4.1. Market Size and Forecast
6.6.5. Egypt
6.6.5.1. Market Size and Forecast
6.6.6. South Africa
6.6.6.1. Market Size and Forecast
6.6.7. Rest of Middle East & Africa
6.6.7.1. Market Size and Forecast

7. Company Profile
7.1. Galderma S.A.
7.1.1. Company Basic Information, Manufacturing Base, Sales Area and Its Competitors
7.1.2. Galderma S.A. Product Category, Application, and Specification
7.1.3. Galderma S.A. Financial Performance (2016-2018)
7.1.4. Main Business/Business Overview
7.2. Allergan Plc
7.3. Mylan N.V.
7.4. Johnson & Johnson
7.5. Mayne Pharma Group Limited
7.6. Sun Pharmaceutical Industries Limited
7.7. Valeant Pharmaceuticals International, Inc.
7.8. Teva Pharmaceutical Industries Ltd.
7.9. Foamix Pharmaceuticals
7.10. Daiichi Sankyo Company, Ltd.